Example: Heart Attack

Search clinical trials for: Trastuzumab

Total 767 results

NCT04538742

Recruiting

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT03742102

Recruiting

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Conditions: Triple Negative Breast Neoplasms
NCT02657343

Active, not recruiting

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Conditions: Breast Cancer
NCT01966471

Active, not recruiting

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Conditions: Breast Cancer
NCT01772472

Active, not recruiting

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Conditions: Breast Cancer
NCT03615326

Recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
NCT03501979

Active, not recruiting

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Conditions: Metastatic Breast Cancer, Leptomeningeal Disease
NCT00781612

Recruiting

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Conditions: Neoplasm Metastasis
NCT04740918

Recruiting

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Conditions: Metastatic Breast Cancer
NCT04589845

Recruiting

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Conditions: Solid Tumors
NCT04309578

Recruiting

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Conditions: Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
NCT04158258

Recruiting

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Conditions: Breast Cancer
NCT03726879

Active, not recruiting

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Conditions: Breast Cancer
NCT02675231

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
NCT01275677

Active, not recruiting

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
NCT00238420

Active, not recruiting

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Conditions: Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
NCT04639219

Recruiting

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
NCT04494425

Recruiting

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Conditions: Advanced or Metastatic Breast Cancer
NCT01273610

Active, not recruiting

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
NCT04632992

Recruiting

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Conditions: Advanced Unresectable or Metastatic Solid Malignancy
NCT04556773

Recruiting

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT03820141

Recruiting

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Conditions: Breast Cancer
NCT04024462

Recruiting

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Conditions: HER2-positive Early Breast Cancer
NCT04351230

Recruiting

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
NCT03199885

Recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Conditions: Breast Adenocarcinoma, Metastatic Breast Adenocarcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma